science
NRx Pharmaceuticals to Report First-Quarter Earnings on May 18
Analysts expect NRx Pharmaceuticals to post a loss of 11 cents per share on $19.43 million in revenue. The company recently received FDA clearance to begin a clinical trial of NRX-101. Several analysts maintained Buy ratings with price targets ranging from $25 to $49.
May 15, 6:32 AM·1m read1 source
forbes.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
NRx Pharmaceuticals, Inc. will release earnings for its first quarter before the opening bell on Monday, May 18. Analysts expect the company to report a quarterly loss of 11 cents per share. That compares with a loss of 34 cents per share in the year-ago period.
43 million, Benzinga reported. On May 7, NRx Pharma received clearance from the FDA to initiate a clinical trial of NRX-101 versus placebo in patients with depression and suicidality. The Wilmington, Delaware-based company trades under the ticker NRXP on NASDAQ.
21 on Thursday. 49 percent, in more recent trading. The article was published on May 15, 2026. Several analysts have maintained Buy ratings on the stock in recent weeks.
D. Boral Capital analyst Jason Kolbert maintained a Buy rating with a price target of $34 on May 5, 2026. Jason Kolbert has an accuracy rate of 47 percent, according to Benzinga.
Ascendiant Capital analyst Edward Woo maintained a Buy rating and increased the price target from $48 to $49 on the same day.
BTIG analyst Thomas Shrader maintained a Buy rating with a price target of $25 on March 24, 2026. Thomas Shrader has an accuracy rate of 58 percent. Benzinga reported on the analyst actions ahead of the earnings release.
